Opicapone News

Opicapone currently has 3 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for Opicapone with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Original indication: Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot...
Evidence level: L5
Predicted indications (20):
- juvenile onset Parkinson disease 19A (99.6%)
- hereditary late onset Parkinson disease (98.9%)
- Rasmussen subacute encephalitis (98.6%)
- atypical juvenile parkinsonism (98.6%)
- X-linked parkinsonism-spasticity syndrome (98.3%)
- myelitis (98.2%)
- PLA2G6-associated neurodegeneration (97.6%)
- paralysis agitans, juvenile, of Hunt (97.3%)
- Parkinson disease (97.0%)
- transaldolase deficiency (96.0%)
- hemiparkinsonism-hemiatrophy syndrome (96.0%)
- fructose-1,6-bisphosphatase deficiency (95.7%)
- Lewy body dementia (95.7%)
- lethal infantile mitochondrial myopathy (95.4%)
- parkinsonian-pyramidal syndrome (95.3%)
- X-linked intellectual disability-ataxia-apraxia syndrome (94.3%)
- early-onset parkinsonism-intellectual disability syndrome (94.2%)
- X-linked intellectual disability-cerebellar hypoplasia syndrome (93.3%)
- CLCN4-related X-linked intellectual disability syndrome (92.5%)
- hydrocephaly-cerebellar agenesis syndrome (91.9%)